This stock is a great choice for cautious and aggressive investors.

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

The best defensive stocks to balance risk and return combine durable cash flows, essential services, and key growth metrics.

Matthew Herper covers medical innovation — both its promise and its perils. It has been a tough year for medicine. The U.S.

CRISPR Therapeutics (NASDAQ: CRSP) soared a few years ago, climbing more than 200% from the start of 2020 through early 2021, ...

According to Gartner, 58% of finance functions employed AI in 2024—a 21-percentage-point jump from the prior year. PwC ...

The leading approach to the simplex method, a widely used technique for balancing complex logistical constraints, can’t get ...

Google Cloud provides access to Gemini models through an offering called the Vertex AI Platform. It’s a broad product suite ...

Alphabet is the most complete end-to-end AI company on the planet, and the advantages of its vertical integration and its ...

FunctionGemma is a 270M-parameter model for function calls that runs on phones and NPUs, helping teams cut cloud costs and ship faster.

Aside from Gemini 3 Flash debut, Google has also pushed Gemini 3 Pro and Nano Banana Pro image generator within the Search ...

According to DataM Intelligence, the global cell and gene therapy market reached a value of US$13.90 billion in 2024 and is ...